Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system, affecting the brain, spinal cord, and optic nerves. It involves inflammation, damage to myelin—the insulating sheath around nerve fibers—and injury to the fibers themselves. The resulting disruption of nerve signaling produces varied neurological symptoms. Its name refers to the multiple areas of scarring, or sclerosis, associated with the disease. (health.nih.gov)

MS is an important cause of neurological disability in young adults, although it can begin at other ages. Its course varies considerably: some people experience relapses followed by partial or complete recovery, while others develop gradually progressive impairment. Genetic susceptibility and environmental exposures contribute to risk, but the processes connecting these factors to disease remain incompletely understood. (health.nih.gov)

Diagnosis combines clinical findings with investigations such as magnetic resonance imaging and cerebrospinal fluid analysis, while excluding alternative explanations. There is no established cure, but disease-modifying treatments, symptom management, and rehabilitation can alter disease activity and support functioning. Understanding MS therefore brings together its epidemiology, immune mechanisms, clinical course, diagnostic criteria, treatment, and wider effects on everyday life. (discovery.ucl.ac.uk)

Disease Definition and Neurological Basis

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system (CNS), combining inflammatory injury, loss of myelin, and degeneration of nerve fibres and nerve cells. Its anatomical targets include the brain, spinal cord, and optic nerves. MS is generally classified as an autoimmune disease because the immune system attacks the body’s own nervous tissue rather than only foreign organisms. “Immune-mediated” describes the established involvement of immune responses without implying that the initiating trigger or the complete sequence of tissue injury has been identified. The disease therefore involves more than damage to an insulating sheath: injury to the underlying neural structures is also fundamental to its neurological effects. (medlineplus.gov)

In normal nervous tissue, a neuron transmits electrical signals along its axon, the elongated process that connects it with other cells. Many axons are surrounded by myelin, a multilayered, lipid-rich membrane produced in the CNS by oligodendrocytes, a type of glial cell. Myelin restricts electrical current leakage and enables rapid signal transmission. It is interrupted at regularly spaced gaps called nodes of Ranvier, where an action potential is regenerated. Current travels beneath the insulated segments to activate the next node, producing saltatory conduction—the apparent “jumping” of the impulse between nodes. For scale, conduction velocities in unmyelinated axons are approximately 0.5–10 metres per second, whereas some myelinated axons can conduct at up to 150 metres per second; these are general physiological ranges, not measurements specific to MS. (ncbi.nlm.nih.gov)

Demyelination is the loss or disruption of this sheath, distinct from destruction of the axon itself. Exposed axonal membrane no longer has the electrical organization required for reliable saltatory conduction, so impulses may slow or fail to propagate. This conduction failure can cause neurological dysfunction even while the axon remains structurally intact. Some function can return when inflammation subsides, electrical properties adapt, or surviving axons acquire new myelin. By contrast, axonal degeneration or transection removes the conducting structure, and neuronal death eliminates the cell itself. These forms of damage contribute to persistent impairment and cannot be reversed simply by replacing myelin. Demyelination and axonal injury coexist in MS rather than forming two completely separate diseases or necessarily occurring only in successive stages. (medlineplus.gov)

The name multiple sclerosis means “multiple areas of scarring.” It refers to the scattered lesions, commonly called plaques, that develop in CNS tissue; disseminated sclerosis is an alternative name. Plaques contain areas of myelin loss, variable axonal injury, and reactive glial changes, although not every lesion is an inactive, mature scar. Lesions occur in both white matter, which contains many myelinated axons, and gray matter, which contains neuronal cell bodies and their connections. Common sites include tissue around the brain’s ventricles, the brainstem, cerebellum, optic nerves, and spinal cord. Their location helps explain why one lesion may disturb vision while another affects movement or coordination. Plaques can be demonstrated by magnetic resonance imaging, but the visible lesions do not encompass every microscopic change in affected nervous tissue. (ninds.nih.gov)

The central location of this injury distinguishes MS from peripheral neuropathy, which affects nerves of the peripheral nervous system outside the brain and spinal cord. Peripheral myelin is produced by Schwann cells rather than oligodendrocytes. Although both central and peripheral disorders can cause weakness, numbness, or impaired conduction, similar symptoms do not establish the same anatomical or disease process. The optic nerve is a CNS structure despite its name; its involvement in MS therefore does not make MS a peripheral neuropathy. (ncbi.nlm.nih.gov)

Recognition and Historical Development

Nineteenth-century recognition of multiple sclerosis began with anatomical observations rather than a diagnostic test. In 1838, the Scottish physician Robert Carswell published illustrations of abnormal patches in the spinal cord and brainstem in his atlas of pathological anatomy. Jean Cruveilhier independently depicted similar lesions in his French atlas, with the relevant plates appearing around 1841; the atlas’s publication in installments explains some earlier disagreements about priority. These illustrations recorded lesions subsequently interpreted as characteristic of MS, but neither author established the full clinical–pathological disease entity. Their significance lies in documenting its anatomical pattern, not in providing modern diagnostic confirmation of every historical patient. (pmc.ncbi.nlm.nih.gov)

At the Salpêtrière in Paris, Jean-Martin Charcot brought together bedside examination and postmortem observation. In May 1868, he delivered three lectures addressing the pathological anatomy, symptoms, and clinical forms of sclérose en plaques. Drawing on earlier reports and observations made with Alfred Vulpian, he described scattered lesions in the spinal cord, medulla, cerebellum, and brain, thereby connecting a variable neurological illness to a recognizable anatomical process. The signs subsequently known as Charcot’s triad were nystagmus, or involuntary rhythmic eye movements; intention tremor, which becomes conspicuous during purposeful movement; and scanning speech, with abnormally separated syllables. Their historical importance was to help distinguish this disorder from other causes of tremor and paralysis; they did not constitute a sensitive or specific modern diagnostic rule. (pmc.ncbi.nlm.nih.gov)

Formal diagnostic frameworks later replaced reliance on a characteristic symptom combination with evidence that disease affected different parts of the central nervous system at different times. The Schumacher criteria of 1965 systematized these requirements, subsequently termed dissemination in space and time. Charles Poser and colleagues’ 1983 criteria incorporated laboratory and other supporting investigations, including cerebrospinal fluid findings, and introduced categories such as “laboratory-supported definite” MS. These frameworks served both clinical classification and the selection of more consistently defined research populations. Their successive changes also mean that diagnostic labels in older studies cannot automatically be equated with those assigned under later criteria. (pmc.ncbi.nlm.nih.gov)

Magnetic resonance imaging made lesions observable during life with substantially greater sensitivity than earlier imaging. In a 1981 study, Ian R. Young and colleagues examined ten patients: computed tomography demonstrated 19 lesions, whereas magnetic resonance scans revealed those abnormalities and 112 additional lesions. In 2001, an international panel chaired by W. Ian McDonald formally integrated MRI into the McDonald criteria, allowing specified imaging evidence to demonstrate dissemination in space and time alongside clinical assessment. Subsequent revisions refined this approach; the 2024 revisions, published in 2025, further incorporated anatomical and biomarker evidence. The detailed requirements belong to the diagnostic framework rather than to the historical symptom triad. (pubmed.ncbi.nlm.nih.gov)

Disease-modifying treatment became an established therapeutic category in the early 1990s. A pivotal randomized controlled trial published in 1993 enrolled 372 ambulatory patients with relapsing–remitting MS. After two years, annual exacerbation rates were 1.27 in the placebo group and 0.84 in the higher-dose interferon beta-1b group, approximately a one-third reduction. On July 23, 1993, the United States Food and Drug Administration approved interferon beta-1b, marketed as Betaseron, the first FDA-approved disease-modifying agent for MS. This milestone established that treatment could reduce subsequent disease activity, rather than solely relieve symptoms or treat individual attacks; the trial’s relapse findings did not demonstrate a cure or reversal of established neurological injury. (neurology.org)

Epidemiology and Population Distribution

Prevalence measures the proportion of a population living with MS at a specified time, whereas incidence measures new cases arising during a defined period, usually expressed per 100,000 person-years. The Multiple Sclerosis International Federation (MSIF) Atlas of MS estimated that 2.8 million people worldwide had MS in 2020, corresponding to 35.9 per 100,000 population. Its survey included 115 countries representing 87% of the world’s population, although only 104 supplied prevalence data. Country estimates drew on registries, administrative records, published studies, and other sources; missing estimates were supplemented through literature searches and pooled rates from 15 geographical subregions. These were synthesized estimates rather than a worldwide census of individually verified cases. (pmc.ncbi.nlm.nih.gov)

The 2024 Atlas update, published on September 3, 2026, estimated 3.1 million people living with MS, or 38.1 per 100,000 population. Rachel King and colleagues assembled contributions from 133 countries representing 93% of the global population; 118 countries supplied prevalence data. The comparison used updated United Nations population denominators for all study years, recalculating the 2020 rate as 35.5 per 100,000 without altering submitted case counts. On that comparable basis, prevalence increased by approximately 7% between 2020 and 2024. Reported regional rates in 2024 were 157.5 per 100,000 in Europe, 108.6 in the Americas, and 3.8 in Africa. These regional figures used contributing countries’ data, whereas the global estimate also included imputed values for missing countries. (pubmed.ncbi.nlm.nih.gov)

Diagnosis commonly occurs in early adulthood: the 2020 Atlas reported a mean diagnostic age of 32 years, although country averages varied. MS also occurs in children and older adults. The 2024 update recorded more than 40,000 people under 18 living with MS across 59 reporting countries, compared with approximately 30,000 across 47 countries in 2020; differences in reporting coverage prevent interpreting these counts as a direct measure of changing childhood risk. Approximately seven in ten people with MS were female in the updated Atlas. This female predominance was observed across regions and income groups, although its magnitude varied between populations. (pmc.ncbi.nlm.nih.gov)

Geographical distribution includes a frequently observed association between higher prevalence and greater distance from the equator, but latitude is not a deterministic exposure. A 2021 analysis of lifetime residence histories from New Zealand’s national prevalence study found that the latitude gradient was already apparent early in life, illustrating why residence at diagnosis alone can misrepresent relevant geography. Population background likewise cannot be reduced to a fixed ancestry-based ranking. In a Southern California cohort covering 2008–2010, Annette Langer-Gould and colleagues identified 496 newly diagnosed cases and found higher incidence among Black than White participants, with lower incidence among Hispanic and Asian participants. These results challenged earlier assumptions that Black populations necessarily had lower risk; the categories and estimates described that particular population, not universal biological boundaries. (pubmed.ncbi.nlm.nih.gov)

Rising prevalence does not by itself establish rising incidence. Earlier diagnosis, improved case detection, more complete registries, longer survival, and population growth can increase the number recorded as living with MS without a corresponding increase in the rate of disease onset. The updated Atlas obtained incidence data from 91 countries, reporting approximately 120,000 new diagnoses annually, but found no clear global incidence trend. Surveillance remains uneven: countries differ in neurologist availability, diagnostic access, record coverage, and the recency of their estimates. Consequently, very low reported prevalence may partly reflect missed diagnoses or incomplete ascertainment, while improved surveillance can produce an apparent increase by identifying previously uncounted cases. (msif.org)

Genetic Susceptibility and Environmental Risk

Susceptibility to multiple sclerosis is polygenic: many genetic variants contribute to risk, together with environmental exposures, rather than a single mutation producing a predictable inheritance pattern. MS therefore does not follow simple dominant, recessive, or sex-linked Mendelian inheritance. Close relatives of affected individuals have increased risk, but familial aggregation is not equivalent to inevitable transmission. A Swedish registry study published in 2014, identifying 28,396 people with MS, estimated that siblings of affected individuals had approximately 7.1 times the risk of matched population controls. This is a relative-risk estimate, not a 71% probability of developing MS; its interpretation depends on the underlying population risk. (medlineplus.gov)

The most firmly established susceptibility allele is HLA-DRB1*15:01, within the human leukocyte antigen region of the major histocompatibility complex on chromosome 6. HLA-DR molecules present protein fragments to T cells, connecting variation in antigen recognition with susceptibility to immune-mediated disease. Other HLA alleles can increase or decrease risk. The broader genetic architecture extends well beyond this region: in 2019, the International Multiple Sclerosis Genetics Consortium analyzed 47,429 cases and 68,374 controls, identifying 200 autosomal susceptibility variants outside the major histocompatibility complex, one X-chromosome variant, and 32 variants within the extended complex. Functional analyses implicated multiple pathways of innate and adaptive immunity, including peripheral immune cells and brain-resident microglia. These findings identify biological pathways associated with susceptibility, rather than a single inherited defect that explains every case. (medlineplus.gov)

Cigarette smoking is associated with increased MS risk, with evidence of an exposure–response relationship. In two Swedish population-based case–control studies reported in 2013, comprising 7,883 cases and 9,264 controls, both smoking duration and intensity contributed independently to the association. Unlike exposures whose effects appear concentrated in adolescence, smoking was associated with risk regardless of age at exposure; the excess association gradually diminished after cessation. Genetic background can modify these relationships. A 2017 study found that smokers carrying HLA-DRB115 and lacking the protective HLA-A02 allele had approximately 12.7-fold higher odds than never-smokers without those genetic risk factors. This comparison combines smoking and genotype differences and must not be interpreted as the effect of smoking alone. (pubmed.ncbi.nlm.nih.gov)

Obesity during adolescence or early adulthood is another associated exposure. In a 2009 analysis of two US nurses’ cohorts, Kassandra Munger, Tanuja Chitnis, and Alberto Ascherio confirmed 593 MS cases. Obesity at age 18, defined as body mass index of at least $30\ \mathrm{kg/m^2}$, was associated with a relative risk of 2.25 compared with the reference weight group, after adjustment for factors including smoking and latitude. Adult body mass was not significantly associated with risk in that analysis, emphasizing the importance of exposure timing. A 2016 Mendelian randomization study using genetic predictors of body mass index provided additional evidence consistent with a causal contribution of higher body mass, although such genetic analyses do not demonstrate that a particular weight-loss intervention prevents MS. (pubmed.ncbi.nlm.nih.gov)

Lower sunlight exposure and lower circulating vitamin D concentrations have also been associated with susceptibility. These are related but not interchangeable exposures: a 2011 Australian case–control study of 216 people with a first demyelinating event and 395 controls found independent associations with past sun exposure and serum 25-hydroxyvitamin D. Its outcome was a first demyelinating event, not necessarily established MS. A 2015 Mendelian randomization study likewise found evidence linking genetically lower vitamin D concentrations with increased MS odds. Nevertheless, observational associations can involve confounding, and genetic estimates of lifelong exposure do not establish the effects of supplementation at a particular age or dose. Such findings support investigation of disease initiation but do not themselves demonstrate that vitamin D supplementation or increased sunlight exposure prevents MS. (pubmed.ncbi.nlm.nih.gov)

Epstein–Barr Virus and Infectious Associations

Epstein–Barr virus (EBV) is a human herpesvirus transmitted principally through saliva. Infection often produces no recognizable symptoms, particularly in childhood; infection during adolescence or adulthood can cause infectious mononucleosis. After primary infection, EBV persists for life in a latent state, principally within B cells, with intermittent reactivation possible. Latency means that the viral genome remains within infected cells without continuous production of infectious virus; it does not mean that the infection has been eliminated. Approximately 90–95% of adults have evidence of previous EBV infection, yet only a small minority develop MS. This disparity is central to interpreting the association: EBV exposure alone is insufficient to explain who develops the disease. (cdc.gov)

The strongest longitudinal evidence came from a study by Kjetil Bjornevik, Alberto Ascherio, and colleagues, published online in Science on January 13, 2022. It examined more than 10 million active-duty United States military personnel followed between 1993 and 2013, among whom 955 received an MS diagnosis during service. Stored serum samples were available for 801 cases and were compared with samples from matched personnel who did not develop MS. Because blood had been collected before neurological symptoms appeared, the investigators could reconstruct the sequence of infection and disease rather than rely on testing performed after diagnosis. Of 35 individuals who subsequently developed MS but initially lacked detectable EBV antibodies, 34 became EBV-positive before MS onset. This change from negative to positive antibody status is termed seroconversion. (pubmed.ncbi.nlm.nih.gov)

MS risk increased approximately 32-fold after EBV seroconversion compared with remaining EBV-negative. This was a relative increase, not a statement that 32% of infected people develop MS. Infection with cytomegalovirus, a herpesvirus with similar transmission patterns, did not show the same association. Serum neurofilament light chain—a biomarker of injury to nerve fibres—rose only after EBV seroconversion among participants who developed MS. The temporal sequence and viral comparison strengthen the evidence for an etiological contribution, rather than merely showing that established MS changes susceptibility to infection. Nevertheless, an observational cohort does not identify the complete causal pathway or establish that infection inevitably produces disease; the results support EBV as an important component in a multistep process involving additional susceptibility factors. (pubmed.ncbi.nlm.nih.gov)

One proposed biological bridge is molecular mimicry, in which an immune response to a microbial molecule also recognizes a structurally similar human molecule. In a separate 2022 Nature study, Tobias Lanz and colleagues identified antibodies derived from cerebrospinal-fluid B cells that recognized both EBV nuclear antigen 1, or EBNA1, and GlialCAM, a protein expressed by cells of the central nervous system. Structural and functional experiments supported cross-reactivity between these targets, and related antibodies were found in a subset of patients rather than universally. These findings provide a specific candidate mechanism linking antiviral immunity to autoimmunity, but do not establish that this mechanism initiates every case or accounts for subsequent disease progression. (nature.com)

Evidence concerning disease causation must also be distinguished from evidence that targeting EBV prevents or treats MS. In May 2022, the US National Institutes of Health launched an early-phase trial of an experimental gp350-ferritin EBV vaccine to assess safety and immune responses, not prevention of MS. A published STOP-MS trial protocol describes testing spironolactone and famciclovir against disability progression in progressive MS; a protocol is not an efficacy result. Preventing primary infection, suppressing viral replication, and altering the consequences of an established latent infection are different interventions. Neither the military-cohort findings nor laboratory cross-reactivity demonstrates that antiviral treatment or EBV vaccination prevents MS; that outcome requires direct clinical evidence. (nih.gov)

Immune Mechanisms and Tissue Pathology

During focal inflammatory lesion formation, activated lymphocytes cross the blood–brain barrier, whose endothelial cells normally regulate entry into nervous tissue. Adhesion molecules help immune cells attach to vessel walls and migrate into perivascular spaces; inflammatory signals alter endothelial function and increase barrier permeability. Within the central nervous system, T cells, B cells, and myeloid cells sustain inflammation through interacting pathways rather than a single destructive mechanism. CD4-positive helper T cells coordinate immune responses through cytokines, while CD8-positive cytotoxic T cells predominate among T cells infiltrating much of the affected brain tissue. Their proximity to injured cells and their clonal expansion support antigen-driven activity, but the relevant targets and the events initiating that activity remain incompletely defined. (pmc.ncbi.nlm.nih.gov)

B cells contribute through antigen presentation to T cells, cytokine secretion, and differentiation into antibody-secreting plasma cells. Their functions therefore extend beyond producing antibodies: inflammatory mediators such as interleukin-6, tumor necrosis factor, and granulocyte–macrophage colony-stimulating factor can reinforce communication between lymphocytes and myeloid cells. Plasma cells within central nervous system compartments produce immunoglobulins, including the restricted antibody populations detected as cerebrospinal-fluid oligoclonal bands. Antibody and complement deposition occurs in some actively demyelinating lesions, supporting antibody-mediated injury in a subset of tissue patterns; it does not establish a single pathogenic antibody shared by all cases. Resident microglia and recruited macrophages engulf damaged myelin and can release reactive oxygen species, nitric oxide, and other inflammatory products. These cells also clear debris and support repair, so their effects depend on their functional state and local environment. (pmc.ncbi.nlm.nih.gov)

The characteristic plaque is a region of myelin loss accompanied by variable injury to oligodendrocytes, axons, and other tissue elements. Active plaques contain numerous phagocytes with ingested myelin fragments; identifying particular myelin proteins within these cells helps pathologists assess the stage of demyelination. Chronic inactive plaques have relatively little ongoing inflammatory destruction and often show astrocytic gliosis—the cellular scarring associated with “sclerosis.” Chronic active, or slowly expanding, plaques instead have a demyelinated center bordered by activated microglia and macrophages, where tissue injury continues. Lesions affect gray as well as white matter, and diffuse abnormalities extend into tissue that appears normal on routine examination. In some later-stage disease, inflammatory cells persist in meningeal and perivascular compartments behind a partly repaired blood–brain barrier, allowing inflammation to continue without the conspicuous leakage associated with newly forming lesions. (pmc.ncbi.nlm.nih.gov)

Demyelination disrupts the organization of ion channels and can slow or block nerve-impulse conduction, producing dysfunction without immediately destroying the underlying axon. Axonal injury, however, is not confined to advanced disease. In a 1998 postmortem study, Bruce D. Trapp and colleagues examined tissue from 11 people with MS and four controls: all 47 examined lesions contained transected axons. Quantified active lesions averaged 11,236 terminal axonal ovoids—markers of severed axons—per cubic millimeter, compared with fewer than one in control normal-appearing white matter. These tissue measurements were not estimates of an individual patient’s rate of neuronal loss. Persistent demyelination also increases axonal energy requirements, while inflammatory oxidative injury can impair mitochondria; the resulting mismatch between energy supply and demand provides a mechanism for further axonal degeneration. Loss of axons, neurons, and their connections contributes to lasting neurological impairment. (pmc.ncbi.nlm.nih.gov)

Repair varies substantially between lesions. Remyelination produces new, usually thinner myelin sheaths, creating partially repaired regions termed “shadow plaques.” Oligodendrocyte precursor cells can generate replacement myelin-forming cells, but their presence does not guarantee successful repair. In 2002, Ansi Chang and colleagues identified premyelinating oligodendrocytes in chronic MS lesions, demonstrating that repair failure cannot always be attributed to an absence of progenitors. Inhibitory tissue signals, incomplete cellular maturation, persistent inflammation, and loss of suitable surviving axons can constrain repair. Tissue studies establish inflammatory demyelination, glial responses, and neuroaxonal injury; proposed initiating sequences—whether immune activation first targets nervous tissue or an initial tissue disturbance recruits immunity—remain mechanistic hypotheses rather than uniformly demonstrated explanations for every lesion. (pmc.ncbi.nlm.nih.gov)

Clinical Manifestations

Visual disturbances include optic neuritis, in which inflammation of the optic nerve produces reduced vision, commonly in one eye, with pain on eye movement and impaired colour perception. Other visual symptoms arise from disturbed control of eye movements rather than optic-nerve injury: double vision reflects misalignment of the eyes, while nystagmus consists of involuntary rhythmic eye movements that may interfere with reading or visual stability. Symptoms vary with the location and severity of damage within the central nervous system; consequently, individuals may experience very different combinations of visual, sensory, motor, and cognitive difficulties. (nice.org.uk)

Sensory manifestations include numbness, tingling, and abnormal or painful sensations affecting the limbs, trunk, or face. Lhermitte’s sign is a brief electric-shock-like sensation travelling down the back, sometimes into the limbs, when the neck bends forwards. Motor involvement can produce weakness, particularly in the arms and legs, together with spasticity—increased muscle tone experienced as stiffness, sometimes accompanied by painful spasms. These impairments may affect walking, standing, or hand use. Coordination difficulties include tremor, clumsiness, and impaired balance; they can occur alongside weakness but are not identical to it. Dizziness may further interfere with balance. Visible gait abnormalities therefore represent several potentially overlapping impairments rather than a single characteristic movement disorder. (nice.org.uk)

Fatigue may be physical, cognitive, or both: examples include exhaustion in the limbs and difficulty sustaining mental effort. It is distinct from muscle weakness and may substantially affect daily activity even when walking and outward appearance remain relatively unchanged. Its causes are not necessarily confined to MS-related neurological injury. NICE’s 2022 guideline identifies sleep disturbance, pain, spasticity, bladder dysfunction, medication effects, infection, anaemia, thyroid dysfunction, anxiety, and depression as possible contributors. Heat and physical or emotional stress can worsen fatigue, while heat or infection can also temporarily intensify other established symptoms. Pain may occur as abnormal sensory experiences or accompany muscle stiffness and spasms; persistent musculoskeletal pain can also be associated with impaired mobility and posture. (ninds.nih.gov)

Bladder dysfunction includes urinary frequency, urgency, and loss of bladder control. Bowel difficulties commonly include constipation. These symptoms reflect disruption of neurological control but are not necessarily proportional to the degree of visible motor impairment. Sexual dysfunction may involve impaired sexual response, including erectile dysfunction, and can have several interacting contributors. Neurological damage may interfere directly with sexual function, while fatigue, spastic muscles, and psychological factors may also contribute. Bladder, bowel, and sexual symptoms can remain less apparent to observers than tremor or walking difficulty, despite their effects on daily functioning and quality of life. (ninds.nih.gov)

Cognitive manifestations include slowed information processing, impaired learning or memory, difficulty concentrating, and reduced ability to multitask or exercise judgment. A 2018 study, Cognitive phenotypes in multiple sclerosis, described cognitive impairment in approximately half of patients, with processing speed and memory particularly affected; such estimates depend on the population and assessment methods. Emotional manifestations include depression, anxiety, mood changes, and difficulty regulating emotional expression. Cognitive complaints do not necessarily indicate a fixed decline: sleep problems, fatigue, depression, anxiety, and medication can influence performance. These less visible manifestations may be present without conspicuous mobility impairment, and cognitive changes may not immediately be recognised by the affected person or associated with MS. (pubmed.ncbi.nlm.nih.gov)

Disease Courses and Early Presentations

Relapsing–remitting MS (RRMS) is characterized by discrete attacks of neurological dysfunction followed by complete or partial recovery, with intervals of relative clinical stability. Recovery need not eliminate all symptoms: an attack can leave persistent impairment. Secondary progressive MS (SPMS) describes a course in which an initially relapsing disease develops sustained, gradual worsening independent of attacks; relapses may continue. Primary progressive MS (PPMS) involves gradual neurological deterioration from the onset, rather than after an established relapsing phase, although plateaus and superimposed attacks can occur. These labels describe clinical patterns within one disease spectrum, not three wholly separate diseases. The transition to SPMS is often recognized retrospectively from repeated assessments rather than identified by a single event or test. (pmc.ncbi.nlm.nih.gov)

The International Advisory Committee on Clinical Trials in MS, including Fred D. Lublin and colleagues, revised the course descriptors in 2013, publishing them in 2014 and clarifying their use in 2020. The framework separates activity from progression. Activity means a clinical relapse or evidence on magnetic resonance imaging (MRI) of a gadolinium-enhancing lesion, a new T2 lesion, or an unequivocally enlarging T2 lesion. Progressive courses are additionally described as “with progression” or “without progression,” according to whether relapse-independent disability accumulation has occurred. Consequently, progressive disease can be active or not active, and absence of relapses does not establish absence of inflammatory activity. The former “progressive-relapsing” category was replaced by PPMS with activity. (pmc.ncbi.nlm.nih.gov)

These modifiers require an explicit observation period, generally assessed at least annually: “SPMS, not active but with progression over the preceding 12 months” is more informative than an undated “inactive SPMS.” If adequate clinical or imaging assessments are unavailable, the corresponding modifier is indeterminate. A relapse is an acute or subacute episode, whereas progression denotes disability accumulating independently of relapses during a progressive course. “Worsening” is the broader term, encompassing both incomplete recovery after attacks and progressive deterioration. Thus, persistent weakness after an attack does not by itself establish SPMS, while gradually declining walking ability without a new attack can represent progression. “Not active” refers only to the specified period and available observations, not permanent disease cessation. (discovery.ucl.ac.uk)

Clinically isolated syndrome (CIS) is a first clinical episode compatible with inflammatory demyelination of the central nervous system when the evidence does not yet establish MS. It may involve the optic nerve, spinal cord, or brainstem. CIS is therefore a presentation category, not a prediction that further attacks will necessarily occur. Characteristic MRI lesions increase the likelihood of subsequently meeting MS diagnostic criteria. Conversely, a person can receive an MS diagnosis after one clinical episode if the required additional evidence is already present; a second clinical attack is not invariably necessary. Successive diagnostic revisions have consequently reduced the number of presentations that remain classified as CIS. (neurology.org)

Radiologically isolated syndrome (RIS) describes incidentally discovered MRI abnormalities characteristic of demyelination without a corresponding clinical attack or progressive neurological impairment; nonspecific white-matter spots alone do not establish RIS. In a multinational study published in 2020 by Christine Lebrun-Frenay and colleagues, extended follow-up was available for 277 of an original 451 participants meeting the 2009 RIS criteria. The estimated cumulative probability of a first clinical event was 51.2% at ten years. Younger age, spinal cord or infratentorial lesions, and oligoclonal bands in cerebrospinal fluid were associated with higher risk; this cohort estimate is not an individual forecast. (neurology.org)

The 2024 McDonald criteria, published in September 2025, allow selected people previously described as having RIS to meet MS diagnostic criteria before a first clinical attack. This requires exclusion of better explanations, characteristic lesions in at least two anatomical locations, and qualifying additional evidence, such as dissemination in time, positive cerebrospinal-fluid findings, or the specified central-vein-sign threshold. An incidental abnormal scan is therefore not automatically an MS diagnosis, and people who do not meet the expanded criteria can remain classified as RIS. (pure.amsterdamumc.nl)

Diagnostic Framework and McDonald Criteria

Multiple sclerosis diagnosis integrates the neurological history, examination, and objective evidence of injury in the central nervous system, together with exclusion of a better explanation. The history establishes whether symptoms occurred as discrete neurological episodes or gradual deterioration; examination assesses whether findings localize to affected pathways. Magnetic resonance imaging (MRI) and laboratory investigations provide complementary evidence. No single test establishes every diagnosis: characteristic lesions must be interpreted in context, while inflammatory findings in cerebrospinal fluid (CSF) can support MS without being exclusive to it. The criteria therefore specify combinations of evidence rather than a universally decisive test. (pmc.ncbi.nlm.nih.gov)

The McDonald criteria, first introduced in 2001 by an international panel led by neurologist Ian McDonald, formalized the integration of clinical and MRI findings. Revisions followed in 2005, 2010, 2017, and 2024. Two central concepts are dissemination in space (DIS), meaning involvement of distinct characteristic CNS regions, and dissemination in time (DIT), meaning evidence of disease activity at different times. These describe the distribution of pathological events, not simply the number or severity of symptoms. Under successive revisions, MRI and CSF evidence increasingly allowed diagnosis without waiting for another clinical attack. (ectrims.eu)

The 2005 revision simplified the MRI requirements for DIT; the 2010 revision allowed it to be demonstrated by a new lesion on follow-up imaging or, under specified conditions, simultaneous enhancing and non-enhancing lesions on one scan. Consequently, some people with a first typical demyelinating episode could meet the criteria at presentation. The 2017 revision, led by Alan Thompson, allowed CSF-specific oligoclonal bands to substitute for DIT when a typical clinically isolated syndrome and DIS were already established. It also admitted symptomatic lesions into relevant assessments of dissemination and cortical lesions into DIS. A positive CSF result alone was not sufficient. (pmc.ncbi.nlm.nih.gov)

The 2024 revisions, published in September 2025 by Xavier Montalban and colleagues, added the optic nerve as a fifth anatomical location, alongside periventricular, cortical or juxtacortical, infratentorial, and spinal cord regions. DIS generally requires typical involvement of at least two of these five locations. Optic nerve involvement can be documented by MRI, optical coherence tomography, or visual evoked potentials, provided another explanation is excluded. In a typical clinical presentation, characteristic lesions in four or five locations can establish MS without separate demonstration of DIT. The revision also provides a unified framework for relapsing and progressive presentations. (ectrims.eu)

Selected biomarker-supported pathways extend this framework. The CSF kappa free-light-chain index is accepted as an alternative to oligoclonal bands. The central vein sign and paramagnetic rim lesions can supply additional MRI specificity in defined circumstances. For example, a typical presentation with lesions confined to one anatomical location can qualify when DIT or positive CSF is accompanied by qualifying central-vein-sign positivity or at least one paramagnetic rim lesion. Certain radiologically isolated presentations can also meet the revised criteria, but incidental lesions alone do not establish MS. (pure.amsterdamumc.nl)

Additional safeguards address presentations at greater risk of misinterpretation. For people aged 50 years or older, or those with significant vascular risk factors, the 2024 panel strongly recommends additional supporting evidence, such as a spinal cord lesion, positive CSF, or qualifying central-vein-sign positivity. Small-vessel ischemic disease and migraine can produce overlapping imaging abnormalities. Atypical clinical or imaging findings therefore require investigation of alternative explanations rather than automatic application of a lesion-counting rule. (pure.amsterdamumc.nl)

Imaging, Cerebrospinal Fluid, and Ancillary Tests

Magnetic resonance imaging (MRI) characterizes lesions by their location, shape, and signal rather than simply counting white-matter abnormalities. Typical brain lesions are focal T2-weighted or fluid-attenuated inversion recovery (FLAIR) hyperintensities in periventricular, cortical or juxtacortical, and infratentorial regions, often involving the corpus callosum. Ovoid periventricular lesions oriented perpendicular to the ventricles—“Dawson’s fingers”—reflect the distribution of inflammation around small veins. Juxtacortical lesions directly abut the cortex. Spinal cord lesions are usually focal, extend over fewer than two vertebral segments, and occupy only part of the cord’s cross-section. Lesions are checked in multiple planes or sequences because motion and cerebrospinal-fluid flow can produce misleading appearances. These morphological distinctions were formalized in the 2019 practical imaging guidelines led by Massimo Filippi. (pmc.ncbi.nlm.nih.gov)

Gadolinium enhancement on T1-weighted images indicates increased blood–brain barrier permeability associated with recent inflammatory activity; enhancement is generally transient, lasting approximately 2–8 weeks and usually less than four weeks. Enhancing and non-enhancing lesions on one examination can therefore represent different stages of lesion development. Serial MRI detects new or enlarging T2 lesions, including clinically silent activity, and supports assessment of disease evolution and treatment response. Comparisons require consistent acquisition protocols and adequate image quality. Lesion burden describes lesion number or volume, not a direct measure of disability: lesion location, tissue destruction, and abnormalities outside visible plaques also matter. Conventional MRI can miss cortical pathology and cannot fully characterize diffuse injury or ongoing progression. The 2024 MAGNIMS–CMSC–NAIMS recommendations, published in 2025, expanded diagnostic imaging guidance to include brain and spinal cord examinations and susceptibility-sensitive sequences. (pmc.ncbi.nlm.nih.gov)

Cerebrospinal fluid (CSF), obtained by lumbar puncture, is assessed alongside a paired serum sample for evidence of intrathecal immunoglobulin production. Oligoclonal bands are detected by isoelectric focusing followed by immunoglobulin-specific detection; at least two IgG bands present in CSF but absent from serum constitute the commonly used positive threshold. Identical bands in both samples do not demonstrate CSF-restricted synthesis. Kappa free light chains (κ-FLC), produced in excess during antibody synthesis, provide a quantitative alternative. The κ-FLC index divides the CSF-to-serum κ-FLC quotient by the CSF-to-serum albumin quotient, accounting for protein transfer from blood. The 2024 McDonald revisions accept κ-FLC evidence interchangeably with oligoclonal bands; accompanying 2025 laboratory guidance identified an index of at least 6.1 as the recommended threshold, subject to assay validation. Neither finding is specific to MS: other inflammatory and infectious neurological disorders can produce intrathecal immunoglobulins. Positive results support the diagnostic framework rather than independently establishing the disease, while negative results do not categorically exclude it. (pmc.ncbi.nlm.nih.gov)

Optical coherence tomography (OCT) measures retinal structures, particularly the peripapillary retinal nerve-fibre layer and macular ganglion-cell–inner plexiform layer, providing structural evidence of visual-system neuroaxonal injury. Visual evoked potentials (VEPs) record electrical responses to visual stimulation; prolonged response latency supports slowed conduction along the visual pathway. OCT and VEP thus measure complementary structural and functional consequences of optic nerve injury. In the 2025 recommendations led by Shiv Saidha, inter-eye thickness differences of at least $6\,\mu\mathrm{m}$ for the peripapillary nerve-fibre layer or $4\,\mu\mathrm{m}$ for the ganglion-cell–inner plexiform layer can support unilateral optic nerve involvement when alternative explanations have been excluded. Interpretation requires quality control and consideration of ocular disease, acute swelling, and bilateral injury. (actrims.org)

Susceptibility-sensitive MRI provides more specialized biomarkers. The central vein sign identifies a small vein running through a lesion, supporting its perivenular origin. Paramagnetic rim lesions show a susceptibility rim associated with iron-containing microglia around chronic white-matter lesions and provide evidence of chronic active pathology rather than merely recent contrast enhancement. Both features can increase diagnostic specificity when conventional imaging is inconclusive, but their assessment depends on suitable sequences, spatial resolution, and trained interpretation. Unlike conventional T2/FLAIR imaging, their implementation is not yet uniform across imaging services; absence of either feature does not exclude MS. (discovery.ucl.ac.uk)

Differential Diagnosis and Diagnostic Error

Neuromyelitis optica spectrum disorder (NMOSD) differs from MS in its biological target and characteristic attack patterns. In aquaporin-4 antibody-positive NMOSD, antibodies target a water-channel protein on astrocytes, with secondary injury to myelin and axons. Severe optic neuritis, spinal cord inflammation extending across three or more vertebral segments, and an area postrema syndrome—otherwise unexplained persistent hiccups, nausea, or vomiting associated with dorsal medullary involvement—favor NMOSD over MS. MS spinal lesions are generally shorter and more peripheral. These patterns are not absolute: NMOSD can produce short spinal lesions, and antibody-negative cases require additional clinical and imaging evidence rather than automatic classification as MS. Serum AQP4-IgG testing by a cell-based assay helps distinguish these disorders. (doi.org)

MOG antibody-associated disease (MOGAD) is also distinct from both MS and AQP4-IgG-positive NMOSD. It can cause bilateral optic neuritis with prominent optic-disc swelling, myelitis involving the conus, or acute disseminated encephalomyelitis (ADEM), especially in children. ADEM combines multifocal neurological deficits with encephalopathy and often large, poorly demarcated brain lesions; it is not simply a severe MS relapse. The 2023 international MOGAD criteria combine a compatible clinical attack, MOG-IgG detected using a cell-based assay, and exclusion of a better explanation. Low-positive antibody results require supporting clinical or imaging features because false positives occur. Other inflammatory alternatives include neurosarcoidosis and neurological manifestations of systemic lupus erythematosus or Sjögren disease. (sciencedirect.com)

White-matter abnormalities on MRI are not synonymous with inflammatory demyelination. Migraine, cerebral small-vessel disease, and normal aging can produce small, rounded deep white-matter lesions. Unlike characteristic MS lesions, these often spare the cortex-adjacent U-fibers and do not directly abut the ventricles. Lesion shape, distribution, and relationship to the clinical syndrome therefore matter more than an unqualified count of “white spots.” Lacunes, microbleeds, and symmetric central pontine abnormalities support vascular alternatives. Neurological deficits reaching maximal severity abruptly suggest stroke or spinal cord infarction rather than the usual subacute evolution of an inflammatory demyelinating attack. Migraine aura and incidental MRI lesions can otherwise be incorrectly combined as evidence of separate MS attacks. (pmc.ncbi.nlm.nih.gov)

Nutritional and structural disorders are particularly important alternatives to progressive spinal presentations. Vitamin B12 or copper deficiency can produce a relatively symmetric myelopathy with long posterior-column abnormalities, sometimes accompanied by peripheral neuropathy. Cervical spondylotic myelopathy causes cord compression from degenerative spinal changes; imaging evidence of compression at the relevant level distinguishes this mechanism from an intrinsic demyelinating plaque, although both conditions can coexist. Infectious alternatives include neurosyphilis, HIV-associated neurological disease, HTLV-1-associated myelopathy, and Lyme neuroborreliosis. Their evaluation depends on the syndrome and exposure history, with organism-specific blood or cerebrospinal fluid tests providing evidence that nonspecific MRI abnormalities cannot supply. (pmc.ncbi.nlm.nih.gov)

Diagnostic error has measurable consequences. In a 2016 study led by Andrew J. Solomon, specialists at four US academic MS centers identified 110 patients with definite or probable MS misdiagnosis. Alternative diagnoses included migraine in 24 patients (22%), fibromyalgia in 16 (15%), and NMOSD in seven (6%). Seventy-seven patients (70%) had received disease-modifying therapy, and 34 (31%) experienced unnecessary morbidity associated with the misdiagnosis. This selected series did not estimate the misdiagnosis rate among all people diagnosed with MS. Its principal identified errors were treating atypical symptoms as demyelinating attacks, accepting historical events without corroborating objective evidence, and overrelying on MRI abnormalities in patients with nonspecific symptoms. (pmc.ncbi.nlm.nih.gov)

Atypical findings prompt reconsideration rather than functioning as automatic exclusions. Prominent fever, meningism, impaired consciousness, severe bilateral visual loss, radicular pain, or unusually extensive spinal lesions can indicate competing diagnoses. When clinical and imaging evidence remain discordant, longitudinal reassessment includes review of the original scans, repeat neurological examination, and comparison of subsequent imaging with the baseline pattern. Serial MRI can reveal characteristic lesion evolution, but new nonspecific lesions do not independently establish MS. Diagnostic criteria must remain anchored to their applicable clinical context and the requirement that no better explanation accounts for the findings. (menactrims.org)

Relapses and Their Clinical Management

A relapse is an episode of new or worsening neurological dysfunction attributable to inflammatory activity in the central nervous system, rather than infection or another explanation. NICE guideline NG220, published in 2022, defines a relapse as symptoms lasting more than 24 hours after a stable period of at least one month, in the absence of infection or another cause. Assessment therefore establishes the timing of symptoms, their relationship to previous deficits, and changes on neurological examination, while excluding particularly urinary tract infection and respiratory infection. Duration alone does not establish a relapse: persistent symptoms may also represent fluctuations in existing impairment or progression. (nice.org.uk)

A pseudo-relapse is the reappearance or intensification of previous symptoms without a new inflammatory attack. Common triggers include infection, fever, and increased body temperature during exercise or exposure to heat; worsening generally subsides when the trigger resolves. Heat-related worsening, termed Uhthoff phenomenon, can reflect reversible conduction failure in previously demyelinated axons, rather than fresh damage to myelin. For example, old visual or walking difficulties may temporarily worsen during fever. Symptoms persisting beyond resolution of the trigger require reassessment. Progressive impairment differs from an attack by its gradual accumulation over time, although progression and relapses can occur in the same individual. (pmc.ncbi.nlm.nih.gov)

Acute treatment aims principally to accelerate recovery and reduce the immediate functional burden. Not every relapse requires medication: a mild sensory episode may have limited consequences, whereas loss of useful vision, marked weakness, or impaired walking may substantially disrupt ordinary activities. NICE recommends early assessment and treatment of functionally significant relapses, within 14 days of onset, and recognizes that severe attacks or unmet medical and social needs may require inpatient care. A clear clinical relapse does not invariably require MRI confirmation; imaging is particularly useful when the presentation is uncertain or unexpectedly severe. Recovery may be incomplete despite treatment, leaving residual disability. (nice.org.uk)

Short courses of high-dose corticosteroids, usually methylprednisolone, suppress inflammatory activity and shorten relapse symptoms, but have not been shown to prevent long-term disability accumulation or alter the underlying disease course. Oral and intravenous administration are both used. In the 2015 COPOUSEP randomized controlled trial, led by Emmanuelle Le Page, 199 participants were assigned to oral or intravenous methylprednisolone. In the per-protocol analysis, 81% of the oral group and 80% of the intravenous group achieved improvement by day 28 without additional corticosteroid treatment, supporting non-inferiority of the oral regimen studied. These results concern equivalent high-dose regimens, not arbitrary substitution between formulations. Adverse effects include insomnia, mood disturbance, gastrointestinal symptoms, elevated blood glucose, and infection risk; corticosteroid treatment for an attack is distinct from long-term disease-modifying therapy. (pmc.ncbi.nlm.nih.gov)

Plasma exchange is a rescue treatment for selected severe attacks that respond inadequately to corticosteroids. It separates and removes plasma while returning blood cells with replacement fluid, reducing circulating antibodies and other soluble inflammatory factors. In a 1999 randomized, sham-controlled crossover trial led by Brian G. Weinshenker, moderate or greater neurological improvement occurred during 8 of 19 active-treatment courses (42.1%), compared with 1 of 17 sham-treatment courses (5.9%). The small study included severe corticosteroid-resistant attacks from several inflammatory demyelinating disorders, not exclusively MS; its percentages therefore do not predict an individual response. Plasma exchange targets an acute inflammatory episode, rather than established progressive impairment, and requires specialist facilities because of risks including hypotension, vascular-access complications, and bleeding or infection. (pubmed.ncbi.nlm.nih.gov)

Disease-Modifying Therapies

Disease-modifying therapies (DMTs) alter immune activity to reduce inflammatory disease activity and, for some treatments and populations, slow disability accumulation; they are distinct from treatments for acute attacks or individual symptoms. Injectable interferon beta modifies immune signalling, whereas glatiramer acetate, a synthetic polypeptide mixture, modifies immune responses through mechanisms that remain incompletely understood. Oral fumarates—including dimethyl fumarate and diroximel fumarate—produce monomethyl fumarate; activation of the Nrf2 cellular stress-response pathway is documented, but does not fully explain their clinical effects. Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for new pyrimidine synthesis, thereby limiting the proliferation of activated immune cells. (menactrims.org)

Sphingosine-1-phosphate receptor modulators—fingolimod, siponimod, ozanimod and ponesimod—restrict lymphocyte exit from lymph nodes, reducing circulating cells available to enter the central nervous system. Monoclonal antibodies target either cell trafficking or immune-cell populations: natalizumab blocks α4-integrin-mediated leukocyte adhesion and migration; ocrelizumab, ofatumumab and ublituximab target CD20-expressing B cells; and alemtuzumab targets CD52, depleting both T and B lymphocytes. Cladribine, an oral purine analogue, also produces lymphocyte depletion through intermittent treatment courses rather than continuous maintenance administration. These mechanisms differ in the depth and duration of immune suppression and in associated safety requirements. (menactrims.org)

Randomized controlled trials measure annualized relapse rates, new or enlarging T2 lesions and contrast-enhancing lesions on MRI, and disability worsening confirmed at a later assessment, commonly after 12 or 24 weeks. Suppressing relapses or MRI lesions does not establish that all progression has stopped. Most DMT indications concern relapsing disease, sometimes explicitly including active secondary progressive MS. Ocrelizumab is also approved in the United States for adult primary progressive MS: in Xavier Montalban and colleagues’ 2017 ORATORIO trial of 732 participants, 12-week-confirmed disability progression occurred in 32.9% receiving ocrelizumab and 39.3% receiving placebo, with a hazard ratio of 0.76. Siponimod’s European indication is specifically secondary progressive MS with activity demonstrated by relapses or inflammatory imaging findings; its US indication covers relapsing forms, including active secondary progressive disease. (menactrims.org)

An escalation strategy starts with a moderate-efficacy treatment and switches to a higher-efficacy agent when disease activity persists; an early high-efficacy strategy uses a potent treatment from the outset. Selection incorporates relapse severity, lesion burden and location, disability trajectory, comorbidities, reproductive considerations and treatment-specific risks. Katharine Harding and colleagues’ 2019 observational study of 592 patients found a smaller mean five-year increase in disability scores with early intensive treatment than with escalation. Such cohort comparisons support early high-efficacy treatment but remain susceptible to confounding and do not establish an identical benefit–risk balance for every patient. (menactrims.org)

Safety surveillance is agent-specific. Dimethyl fumarate requires blood-count monitoring because prolonged lymphopenia increases opportunistic-infection risk; teriflunomide requires liver surveillance. Ocrelizumab’s prescribing information specifies hepatitis B screening and quantitative immunoglobulin assessment, with continued monitoring for reduced immunoglobulins and infections. Alemtuzumab can cause delayed secondary autoimmunity, including thyroid disease, immune thrombocytopenia and kidney disease; its US monitoring programme includes monthly blood and urine testing until 48 months after the last course. Progressive multifocal leukoencephalopathy (PML), a potentially fatal JC-virus infection of the brain, is particularly associated with natalizumab. Established risk factors include anti-JC-virus antibodies, longer exposure and previous immunosuppressant use; PML has also been reported with other DMTs. (dailymed.nlm.nih.gov)

Treatment interruption does not immediately eliminate biological effects or safety risks. Severe disease reactivation can follow fingolimod withdrawal, while natalizumab interruption can permit renewed inflammatory activity; switching therefore involves balancing treatment gaps against overlapping immune effects. Regulatory approval is distinct from off-label prescribing: rituximab is used off-label for MS in some settings, despite not having an MS-specific US approval. Authorized indications, reimbursement and regional availability differ, so evidence of efficacy does not itself imply that a medicine is licensed or accessible for every disease course or jurisdiction. (dailymed.nlm.nih.gov)

Symptom Management and Rehabilitation

Symptom-directed treatment and rehabilitation address discomfort, functional limitations, and participation in daily activities; their benefits are distinct from suppression of inflammatory disease activity. Treatment of spasticity illustrates the importance of functional goals: reducing stiffness may ease pain or personal care, but some people depend on increased muscle tone to stand or transfer, so excessive relaxation can worsen function. Assessment includes aggravating factors such as infection, bladder or bowel dysfunction, pressure injuries, and poor positioning. The 2022 NICE guideline identifies oral baclofen as a first-line option and gabapentin as an alternative when baclofen is ineffective or poorly tolerated, with specialist multidisciplinary assessment for persistent problems. Neuropathic pain is distinguished from musculoskeletal pain caused by posture, immobility, or abnormal movement. Medicines used for neuropathic pain include amitriptyline, duloxetine, gabapentin, and pregabalin; musculoskeletal pain instead requires treatment directed at its mechanical cause. Symptom improvement is assessed alongside adverse effects and effects on everyday function. (nice.org.uk)

Urinary management distinguishes impaired storage—urgency, frequency, and leakage—from incomplete emptying. Assessment can include ultrasound measurement of residual urine after voiding. Antimuscarinic medicines reduce bladder muscle responses to cholinergic stimulation and can improve overactive-bladder symptoms, but may worsen retention, constipation, or cognition. Behavioral approaches include bladder training and scheduled voiding; intermittent catheterization can assist inadequate emptying. Bladder-wall botulinum toxin injections are used in selected patients whose overactive-bladder symptoms persist despite, or cannot tolerate, antimuscarinic treatment. Because injections can cause retention, treatment planning includes the possible need for catheterization. These interventions manage urinary function rather than the underlying inflammatory process. (nice.org.uk)

Multidisciplinary rehabilitation combines neurological and rehabilitation medicine with physiotherapy, occupational therapy, specialist nursing, speech and language therapy, and psychological or neuropsychological services according to the deficits present. Physiotherapy addresses strength, balance, gait, and transfers; occupational therapy uses task practice, adaptations, and compensatory methods for activities such as dressing and preparing meals. Speech and language interventions address communication difficulties, while swallowing management may include altered food consistency, positioning, and swallowing maneuvers selected after assessment. Cognitive interventions target attention, memory, and executive difficulties through structured practice and compensatory aids. Goals are expressed as achievable activities—such as transferring safely or completing a household task—rather than solely as changes in neurological examination findings. (nice.org.uk)

Fatigue assessment includes sleep disturbance, pain, bladder symptoms, medication effects, infection, anemia, thyroid dysfunction, and depression, rather than automatically attributing all tiredness to MS. Nonpharmacological approaches include energy conservation, prioritization of activities, cognitive behavioral techniques, and adapted aerobic, resistance, or balance exercise. Drug evidence is inconsistent: Bardia Nourbakhsh and colleagues’ randomized, double-blind crossover trial, published in 2021, enrolled 141 participants and found that amantadine, modafinil, and methylphenidate were not superior to placebo for fatigue overall. Adverse events occurred in 39–40% of participants during active-drug periods, compared with 31% during placebo treatment. This finding limits claims of broadly reliable benefit from these medicines without establishing that every individual response is identical. (nice.org.uk)

Assistive technology includes orthoses, walking aids, wheelchairs, transfer equipment, and environmental adaptations; compensatory aids can support cognitive as well as physical independence. Equipment selection is linked to the activity being supported and includes training in its use. A 2019 Cochrane overview by Bhasker Amatya, Fary Khan, and Mary Galea included 15 reviews encompassing 164 randomized trials and four other controlled trials, with 10,396 participants. It found moderate-certainty evidence that exercise and physical activity improved mobility, strength, fatigue, and quality of life, and that multidisciplinary rehabilitation improved activity and participation. Evidence for several other approaches was less certain or inconclusive, reflecting heterogeneous interventions, limited robust studies, and incomplete coverage of newer research. Functional gains therefore cannot be interpreted as proof of remyelination or prevention of disease progression. (nice.org.uk)

Childhood, Later-Life Onset, and Pregnancy

Pediatric-onset MS denotes disease beginning before age 18. Its early course can be highly inflammatory without immediately producing substantial physical disability. A cohort study published in 2013, comparing 84 pediatric-onset with 258 adult-onset cases, found a 2.30-fold higher relapse rate in the pediatric group over the first six years, although disability scores did not differ significantly. A separate prospective comparison published in 2020 found better recovery from attacks in children than in adults. Thus, frequent childhood relapses and relatively complete short-term recovery can coexist; recovery does not establish that the disease is harmless or nonprogressive. (pubmed.ncbi.nlm.nih.gov)

Childhood diagnosis requires particular attention to other inflammatory demyelinating disorders. MOG antibody-associated disease can cause optic neuritis, spinal cord inflammation, or acute disseminated encephalomyelitis (ADEM), especially in younger children, and may itself relapse. The 2024 McDonald criteria provide a shared pediatric and adult framework but include pediatric safeguards: after an ADEM presentation, subsequent MS-typical attacks or new, characteristically located lesions more than 90 days later are required before applying the criteria. Cell-based MOG-IgG testing is strongly recommended for children under 12 with a first central nervous system demyelinating event, and for older children with atypical or MOG-suggestive presentations. Pediatric treatment also has direct trial evidence: the 2018 PARADIGMS randomized trial reported annualized relapse rates of 0.12 with fingolimod and 0.67 with interferon beta-1a, an 82% relative difference. (ejpn-journal.com)

Late-onset MS generally means first symptoms at age 50 or older; very-late-onset MS begins at 60 or older. This differs from longstanding MS in a person who has aged with the disease. Progressive presentations are proportionally more frequent than in younger-onset populations. Diagnostic interpretation is complicated by cerebrovascular disease and other age-associated conditions: vascular white-matter abnormalities can resemble demyelination on MRI, while comorbid illness can contribute independently to mobility or cognitive impairment. The 2024 criteria consequently emphasize additional supporting evidence in people aged 50 or older or with vascular risk factors, including spinal cord lesions, positive cerebrospinal fluid findings, or the central vein sign. Older adults remain poorly represented in treatment trials, and age-associated immune changes and comorbidity complicate estimates of treatment benefit and infection risk. (nature.com)

Disease activity often changes during pregnancy and after delivery. In Christian Confavreux and colleagues’ 1998 Pregnancy in Multiple Sclerosis (PRIMS) study, 254 women underwent 269 pregnancies across 12 European countries. Mean annualized relapse rates fell from 0.7 in the preceding year to 0.2 during the third trimester, then rose to 1.2 during the first three postpartum months before returning toward baseline. These are annualized rates, not the proportion experiencing an attack within each trimester. The study found no apparent postpartum acceleration of disability. A 2020 meta-analysis encompassing 7,034 pregnancies confirmed declining relapse activity during pregnancy and a postpartum increase, but also found substantial variation between studies and lower prepregnancy and postpartum rates in more recent cohorts. (pubmed.ncbi.nlm.nih.gov)

Medication exposure and treatment interruption are separate determinants of pregnancy-associated outcomes. A 2024 observational study of 350 natalizumab-exposed pregnancies found fewer maternal relapses when treatment continued beyond the first trimester than when it stopped during that trimester. Exposure at or beyond gestational week 30 was associated with more neonatal anemia and thrombocytopenia. These findings illustrate the competing outcomes of maternal disease control and fetal exposure rather than establishing a universally applicable treatment schedule. (pubmed.ncbi.nlm.nih.gov)

Breastfeeding introduces another distinction between maternal relapse activity and infant drug exposure. A 2020 meta-analysis of 24 studies involving 2,974 women associated breastfeeding with fewer postpartum relapses, particularly with exclusive breastfeeding; its observational evidence cannot fully separate breastfeeding from differences in disease activity and treatment choices. Drug-exposure evidence is medication-specific. In a 2020 German registry study of 74 infants breastfed during maternal interferon beta or glatiramer acetate treatment, first-year growth, development, hospitalization, and antibiotic-use outcomes were broadly consistent with population expectations. The sample was too small to exclude rare adverse events, and those findings do not establish equivalent lactation safety for other MS medicines. (pmc.ncbi.nlm.nih.gov)

Disability Measurement and Long-Term Outcomes

Neurological examination measures impairment in specific functions rather than reducing disease severity to the number of attacks or lesions. Strength, muscle tone, coordination, sensation, vision, and walking are assessed alongside bowel and bladder function. John F. Kurtzke’s Expanded Disability Status Scale (EDSS), published in 1983, combines functional-system ratings with walking ability and, at higher scores, dependence in daily activities. It ranges from 0, indicating a normal neurological examination, to 10, indicating death attributed to MS; intermediate scores run from 1.0 to 9.5 in half-point steps. Scores of 1.0–1.5 represent abnormal examination findings without disability, whereas 6.0 indicates the need for a unilateral walking aid and 6.5 for bilateral assistance. These are clinical categories, not equal units of impairment: a one-point increase has different implications at different positions on the scale. Its middle range is dominated by walking, and it incompletely captures cognition and other dimensions of disability. (pubmed.ncbi.nlm.nih.gov)

Performance tests provide complementary, quantitative measurements. The Multiple Sclerosis Functional Composite (MSFC), developed by a National Multiple Sclerosis Society task force and reported in 1999, combines the Timed 25-Foot Walk for ambulation, the Nine-Hole Peg Test for hand dexterity, and the Paced Auditory Serial Addition Test for cognitive performance. Component results are standardized against a reference population and averaged, allowing changes in different functional domains to contribute to one score. Nevertheless, the reference population affects the composite’s interpretation, and repeated testing can produce practice effects rather than genuine improvement. Reporting individual component results therefore preserves information that an aggregate score can conceal. The US National Institute of Neurological Disorders and Stroke’s common-data-element framework supports standardized outcome collection while emphasizing that instruments must match each study’s aims. (pubmed.ncbi.nlm.nih.gov)

Patient-reported outcomes measure experiences that examination and timed tasks do not directly establish. Jeremy Hobart and colleagues introduced the Multiple Sclerosis Impact Scale (MSIS-29) in 2001: its 20 physical and nine psychological items assess the patient-perceived impact of disease. Such instruments complement rather than replace objective testing. Physical impairment, perceived disease impact, and quality of life are related but distinct outcomes; a scale centered on mobility cannot fully represent psychological burden. A longitudinal study published in 2024, involving 5,921 participants, found that MSIS-29 domains differed across clinical and demographic characteristics, including employment and marital status, illustrating why patient-reported impact cannot be inferred from an EDSS score alone. (pubmed.ncbi.nlm.nih.gov)

Inflammatory activity and accumulated disability also require separate assessment. Relapses and new lesions on magnetic resonance imaging indicate disease activity, whereas disability may accumulate through incomplete relapse recovery or worsening outside recognized attacks. Trials commonly require deterioration to remain present at a later assessment—for example, after 12 or 24 weeks—rather than count every transient change. In Ludwig Kappos and colleagues’ 2020 pooled analysis of 1,656 OPERA I and II participants with relapsing MS, progression independent of relapse activity accounted for 78.0% of participants with 12-week-confirmed composite disability accumulation in the interferon group and 88.0% in the ocrelizumab group. The composite included EDSS, walking, and hand-function measurements. These percentages describe contributors among participants who accumulated disability, not the proportion of all participants who progressed; “independent of relapse” denotes a temporal classification, not proof that inflammation was absent. (pubmed.ncbi.nlm.nih.gov)

Long-term prognosis is variable and dependent on the population, treatment era, and outcome definition. A historical Canadian study of 1,099 patients followed between 1972 and 1984 estimated a median of approximately 15 years from onset to requiring walking assistance, but its subgroup observed from onset reached that milestone in approximately 9.4 years. Even within one study, cohort selection substantially changed the estimate. Historical pretreatment trajectories cannot be transferred directly to patients receiving contemporary disease-modifying care. In Katharine Harding and colleagues’ 2019 observational cohort of 592 patients, mean five-year EDSS increases were 0.3 with early intensive treatment and 1.2 with an escalation strategy. The association remained after adjustment, but nonrandomized treatment allocation leaves scope for confounding. Such studies provide group-level estimates under specified conditions, not an individual timetable for disability. (pubmed.ncbi.nlm.nih.gov)

Everyday Life, Care Systems, and Disease Burden

Employment and education can be affected by fluctuating symptoms as well as sustained disability. Reduced mobility may limit physically demanding work or travel, while fatigue, pain, and cognitive difficulties can interfere with concentration, pace, and attendance even when impairment is not outwardly apparent. A Swedish survey study published in 2024 found that 62.5% of employed participants identified symptoms classified as invisible as their most limiting symptoms; this describes the surveyed workforce, not all people with MS. Such symptoms can also be less readily recognized as grounds for workplace support. Adjustments described by the Multiple Sclerosis International Federation (MSIF) include flexible hours and rest facilities at work, and changes to educational timetables or examinations. Vocational rehabilitation addresses the relationship between functional capacity and job demands through assessment, career counselling, workplace adaptation, or retraining, rather than assuming that diagnosis necessarily requires withdrawal from employment. (pmc.ncbi.nlm.nih.gov)

Daily participation also depends on access to transport, suitable housing, personal assistance, and leisure activities. Driving and travel difficulties can restrict access to work, appointments, and social contact; home adaptations and mobility equipment address environmental barriers rather than the underlying disease. In its 2022 adult-MS guideline, the United Kingdom’s National Institute for Health and Care Excellence (NICE) includes driving, transport, employment, family circumstances, leisure, and home equipment in the comprehensive review recommended at least annually. Its supporting evidence review identifies social isolation and access to social services as important concerns in advanced disease. These domains distinguish participation and quality of life from neurological impairment alone. (nice.org.uk)

Families and unpaid caregivers may support personal care and everyday activities, while changing care requirements can affect their own employment, education, and relationships. NICE’s MS guidance includes caregiver information and assessment, alongside access to occupational therapy and social care; its adult-carer guideline addresses balancing caring with work or study. Coordinated care connects neurological services, MS nurses, rehabilitation, primary care, and social services through multidisciplinary assessment and referrals. The annual review provides one mechanism for identifying needs that medication-focused visits may miss. NICE’s 2022 evidence review nevertheless distinguished the recognized importance of coordination from uncertainty about which organizational processes and professional roles deliver it most effectively and cost-effectively. (nice.org.uk)

Access to these services differs markedly across health systems. The Atlas of MS 2020 clinical-management survey documented barriers involving specialist personnel, diagnostic infrastructure, medicines, and supportive care. MSIF’s treatment-access analysis reported that 14% of surveyed countries had no licensed disease-modifying therapy available, rising to 70% among low-income countries; 72% reported barriers to accessing these therapies. These are country-level expert reports, not percentages of patients receiving treatment. Cost to governments, insurers, or health systems was the most commonly reported treatment barrier, while irregular supply and reimbursement procedures could interrupt continuing treatment. Diagnostic barriers likewise included limited awareness, professional training, and access to diagnostic resources. Rehabilitation and social support therefore form part of the access problem, not merely optional additions after medicines become available. (msif.org)

Registries and patient organizations make aspects of this burden visible beyond routine clinical records. The UK MS Register collects repeated patient questionnaires and works with clinical partner sites; its employment data include disclosure of diagnosis and workplace modifications. MSIF and national organizations use Atlas findings to document resource gaps, inform policy discussions, and provide information about education, employment, and local support. Such data serve different purposes: individual registries follow lived experience and outcomes, whereas the Atlas compares national resources and reported access barriers. (ukmsregister.org)

International initiatives connect MS care with broader neurological-health policy. In May 2022, World Health Organization member states adopted the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2031, covering timely care, governance, research, and information systems, including the needs of carers and families. On July 26, 2023, WHO added cladribine, glatiramer acetate, and rituximab to its Model List of Essential Medicines for MS. The list guides national selection and procurement in support of universal health coverage; inclusion does not itself ensure local availability or constitute national regulatory approval, and WHO explicitly identified rituximab’s MS use as off-label. (who.int)

Research Methods and Unresolved Questions

Randomized controlled trials test whether interventions alter relapses, imaging activity, disability accumulation, or repair-related outcomes; longitudinal cohorts examine changes over years and outcomes that short trials may miss. For example, a 2022 observational study followed 5,169 people with clinically isolated syndrome or early relapsing–remitting disease for at least five years, distinguishing relapse-associated worsening from progression independent of relapse activity. Standardization makes such studies more comparable: the US National Institute of Neurological Disorders and Stroke developed its first multiple-sclerosis Common Data Elements in 2011, covering biospecimens, clinical assessments, imaging, and cognition. Shared definitions and case-report forms support consistent data collection without making different study populations or designs interchangeable. (pubmed.ncbi.nlm.nih.gov)

Biospecimen research uses blood and cerebrospinal fluid to investigate immune activity and tissue injury. Neurofilament light chain, an axonal structural protein released during injury, is a leading biomarker candidate for monitoring disease activity and treatment response. A 2024 consensus led by Mark S. Freedman described its potential clinical contribution, while emphasizing interpretation alongside examination and imaging rather than as a stand-alone test. Its concentration is influenced by factors including age and other causes of neurological injury. Imaging research likewise examines processes beyond new lesions: paramagnetic rims and slowly expanding lesions are candidate measures of chronic active pathology. A 2024 consensus stressed that these measures have different relationships to histopathological lesions and require further standardization. (pubmed.ncbi.nlm.nih.gov)

Remyelination research seeks to promote the differentiation of oligodendrocyte precursor cells and restoration of myelin around surviving axons. Neural repair therefore requires different evidence from suppression of inflammation. In Ari J. Green and colleagues’ 2017 ReBUILD trial, 50 participants with chronic demyelinating optic neuropathy received clemastine or placebo in a randomized crossover design. Clemastine shortened visual-evoked-potential latency by 1.7 milliseconds per eye, providing a physiological signal consistent with repair, not proof of sustained disability reversal. Safety and disease context remain important: a 2025 TRAP-MS report described stopping its clemastine arm after three of nine participants with progressive disease met predefined safety criteria for accelerated disability progression. A positive experimental endpoint cannot establish that an intervention is broadly effective or safe. (pubmed.ncbi.nlm.nih.gov)

Autologous hematopoietic stem-cell transplantation is an immune-directed intervention, not direct replacement of damaged neurons. Hematopoietic cells are collected from the patient; conditioning treatment suppresses or depletes immune populations, and reinfusion supports hematopoietic and immune reconstitution. Richard K. Burt and colleagues’ 2019 MIST trial randomized 110 participants with active relapsing–remitting disease to transplantation or another disease-modifying treatment and found longer time to disability progression with transplantation. The study does not establish equivalent benefit across all disease courses. The 2025 ECTRIMS–EBMT consensus recognized transplantation as an option for selected treatment-refractory relapsing disease, while identifying unresolved questions about its placement relative to high-efficacy medicines. Conditioning-related toxicity, infection, infertility, and transplant-related mortality distinguish it from routine drug treatment. (pubmed.ncbi.nlm.nih.gov)

Prevention research must distinguish an etiological association from demonstrated prevention. Evidence linking Epstein–Barr virus infection to subsequent disease provides a rationale for vaccine-based studies, but preventing infection or infectious mononucleosis is not itself evidence of reduced multiple-sclerosis incidence. A 2025 methodological analysis estimated that direct prevention studies could require hundreds of thousands of participants and decades of observation, and considered post-licensure designs as alternatives. Such studies must measure disease incidence rather than infer preventive efficacy solely from antibody responses. (pubmed.ncbi.nlm.nih.gov)

Unresolved questions concern why disease begins in only some susceptible individuals, why repair becomes inadequate, and why disability can accumulate without recognized relapses. Longitudinal cohorts document this latter pattern but do not, by themselves, identify its biological cause. Imaging of chronic active lesions provides one route to investigating persistent inflammation, while repair trials test whether physiological changes translate into durable functional benefit. Predicting an individual’s treatment response remains another distinct challenge: a marker associated with injury or prognosis is not automatically a validated tool for choosing between therapies. (pubmed.ncbi.nlm.nih.gov)

References

1. Multiple sclerosis: MedlinePlus Geneticsmedlineplus.gov
2. Multiple sclerosis: MedlinePlus Medical Encyclopediamedlineplus.gov
3. Strategies for Future Research on Disease Mechanisms - Multiple Sclerosis - NCBI Bookshelfncbi.nlm.nih.gov
4. Increased Conduction Velocity as a Result of Myelination - Neuroscience - NCBI Bookshelfncbi.nlm.nih.gov
5. Multiple Sclerosis | MS | MedlinePlusmedlineplus.gov
6. Clinical and Biological Features - Multiple Sclerosis - NCBI Bookshelfncbi.nlm.nih.gov
7. Multiple Sclerosis: Hope Through Researchninds.nih.gov
8. Transverse Myelitis | National Institute of Neurological Disorders and Strokeninds.nih.gov
9. The 150th anniversary of the first depiction of the lesions of multiple sclerosispmc.ncbi.nlm.nih.gov
10. One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological diseasepmc.ncbi.nlm.nih.gov
11. Clinical trials in multiple sclerosis: milestonespmc.ncbi.nlm.nih.gov
12. The diagnosis of multiple sclerosis and the clinical subtypespmc.ncbi.nlm.nih.gov
13. Nuclear magnetic resonance imaging of the brain in multiple sclerosispubmed.ncbi.nlm.nih.gov
14. Purple Book Search: Betaseronpurplebooksearch.fda.gov
15. Disease Modifying Agents for Multiple Sclerosispmc.ncbi.nlm.nih.gov
16. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third editionpmc.ncbi.nlm.nih.gov
17. Global prevalence of multiple sclerosis surpasses 3 million: 2024 update of the Multiple Sclerosis International Federation Atlas of MSpubmed.ncbi.nlm.nih.gov
18. Number of people living with MS across the world surpasses 3 million for the first timemsif.org
19. The latitude gradient for multiple sclerosis prevalence is established in the early life coursepubmed.ncbi.nlm.nih.gov
20. Incidence of multiple sclerosis in multiple racial and ethnic groupspubmed.ncbi.nlm.nih.gov
21. Black Women Have Higher Incidence of MS than White Womenkp-scalresearch.org
22. Modest familial risks for multiple sclerosis: a registry-based study of the population of Swedenpubmed.ncbi.nlm.nih.gov
23. Multiple Sclerosis Genomic Map implicates peripheral immune cells & microglia in susceptibilitypmc.ncbi.nlm.nih.gov
24. Smoking and multiple sclerosis susceptibilitypubmed.ncbi.nlm.nih.gov
25. The interaction between smoking and HLA genes in multiple sclerosis: replication and refinementpubmed.ncbi.nlm.nih.gov
26. Body size and risk of MS in two cohorts of US womenpubmed.ncbi.nlm.nih.gov
27. Obesity and Multiple Sclerosis: A Mendelian Randomization Studypubmed.ncbi.nlm.nih.gov
28. Sun exposure and vitamin D are independent risk factors for CNS demyelinationpubmed.ncbi.nlm.nih.gov
29. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Studypmc.ncbi.nlm.nih.gov
30. About Epstein-Barr Virus (EBV)cdc.gov
31. Study suggests Epstein-Barr virus may cause multiple sclerosisbeta.nih.gov
32. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosispubmed.ncbi.nlm.nih.gov
33. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosismedia.tghn.org
34. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAMnature.com
35. Breaching Brain Barriers: B Cell Migration in Multiple Sclerosispmc.ncbi.nlm.nih.gov
36. Multiple Sclerosis Pathologypmc.ncbi.nlm.nih.gov
37. B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammationpmc.ncbi.nlm.nih.gov
38. Microglia in the context of multiple sclerosispmc.ncbi.nlm.nih.gov
39. Mechanisms underlying progression in multiple sclerosispubmed.ncbi.nlm.nih.gov
40. Mechanisms of Neuronal Dysfunction and Degeneration in Multiple Sclerosispmc.ncbi.nlm.nih.gov
41. Microglia in Multiple Sclerosis: Friend or Foe?pmc.ncbi.nlm.nih.gov
42. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosispubmed.ncbi.nlm.nih.gov
43. The immuno-pathophysiology of multiple sclerosispmc.ncbi.nlm.nih.gov
44. Recommendations | Multiple sclerosis in adults: management | Guidance | NICEnice.org.uk
45. Multiple sclerosis | World Health Organizationwho.int
46. Optic neuritis: MedlinePlus Medical Encyclopediamedlineplus.gov
47. Characteristics and Management of Major Symptoms - Multiple Sclerosis - NCBI Bookshelfncbi.nlm.nih.gov
48. Multiple Sclerosis (MS) | Healthhealth.nih.gov
49. Symptoms & Causes of Erectile Dysfunction - NIDDKniddk.nih.gov
50. Cognitive phenotypes in multiple sclerosis - PubMedpubmed.ncbi.nlm.nih.gov
51. Defining the clinical course of multiple sclerosis: The 2013 revisionspmc.ncbi.nlm.nih.gov
52. The 2013 clinical course descriptors for multiple sclerosis: A clarificationpubmed.ncbi.nlm.nih.gov
53. The 2013 clinical course descriptors for multiple sclerosis: A clarificationdiscovery.ucl.ac.uk
54. Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Eventpubmed.ncbi.nlm.nih.gov
55. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriapure.amsterdamumc.nl
56. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriapmc.ncbi.nlm.nih.gov
57. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriapubmed.ncbi.nlm.nih.gov
58. McDonald Diagnostic Criteriaectrims.eu
59. Diagnosis of MS: 2024 Revisions of the McDonald Criteriaectrims.eu
60. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelinespmc.ncbi.nlm.nih.gov
61. 2024 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisdiscovery.ucl.ac.uk
62. Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosispmc.ncbi.nlm.nih.gov
63. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statementpmc.ncbi.nlm.nih.gov
64. The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosisactrims.org
65. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosisdoi.org
66. Clinical presentation and diagnosis of multiple sclerosispmc.ncbi.nlm.nih.gov
67. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelinesmenactrims.org
68. The differential diagnosis of multiple sclerosispmc.ncbi.nlm.nih.gov
69. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter studypmc.ncbi.nlm.nih.gov
70. Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapsespmc.ncbi.nlm.nih.gov
71. The effect of temperature on a simulated systematically paranodally demyelinated nerve fiberpubmed.ncbi.nlm.nih.gov
72. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trialpubmed.ncbi.nlm.nih.gov
73. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating diseasepubmed.ncbi.nlm.nih.gov
74. Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practicepmc.ncbi.nlm.nih.gov
75. DailyMed — COPAXONE, glatiramer acetate injectiondailymed.nlm.nih.gov
76. TECFIDERA prescribing informationdailymed.nlm.nih.gov
77. DailyMed — AUBAGIO, teriflunomide tabletdailymed.nlm.nih.gov
78. DailyMed — GILENYA, fingolimod capsuledailymed.nlm.nih.gov
79. TYSABRI prescribing informationdailymed.nlm.nih.gov
80. OCREVUS prescribing informationdailymed.nlm.nih.gov
81. DailyMed — LEMTRADA, alemtuzumab injectiondailymed.nlm.nih.gov
82. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosispubmed.ncbi.nlm.nih.gov
83. Mayzent — European Medicines Agencyema.europa.eu
84. DailyMed — MAYZENT, siponimod tabletdailymed.nlm.nih.gov
85. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosispubmed.ncbi.nlm.nih.gov
86. Recommendations | Neuropathic pain in adults: pharmacological management in non-specialist settings | Guidance | NICEnice.org.uk
87. Recommendations | Urinary incontinence in neurological disease: assessment and management | Guidance | NICEnice.org.uk
88. Designing and commissioning rehabilitation services | Rehabilitation for chronic neurological disorders including acquired brain injury | Guidance | NICEnice.org.uk
89. Rehabilitation to maintain, improve or support function | Rehabilitation for chronic neurological disorders including acquired brain injury | Guidance | NICEnice.org.uk
90. Rehabilitation to maintain, improve or support function | Rehabilitation for chronic neurological disorders including acquired brain injury | Guidance | NICEnice.org.uk
91. Comparing Medicines to Help Patients with Multiple Sclerosis Feel Less Fatigued—The TRIUMPHANT-MS Studyncbi.nlm.nih.gov
92. Rehabilitation for persons with multiple sclerosis | Cochranecochrane.org
93. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 yearspubmed.ncbi.nlm.nih.gov
94. Improved relapse recovery in paediatric compared to adult multiple sclerosispubmed.ncbi.nlm.nih.gov
95. 2024 revisions of the McDonald criteria: slide deckectrims.eu
96. Advancing multiple sclerosis management in older adultsnature.com
97. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Grouppubmed.ncbi.nlm.nih.gov
98. Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysispubmed.ncbi.nlm.nih.gov
99. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancypubmed.ncbi.nlm.nih.gov
100. Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysispmc.ncbi.nlm.nih.gov
101. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomespmc.ncbi.nlm.nih.gov
102. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)pubmed.ncbi.nlm.nih.gov
103. Expanded Disability Status Scale (EDSS)secure.nationalmssociety.org
104. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessmentpubmed.ncbi.nlm.nih.gov
105. Intrarater and interrater reliability of the MS functional composite outcome measurepubmed.ncbi.nlm.nih.gov
106. The multiple sclerosis functional composite: different practice effects in the three test componentspubmed.ncbi.nlm.nih.gov
107. NINDS Multiple Sclerosis Common Data Element (CDE): Outcomes and Neurological and Physical Exam Subgroup Recommendationscommondataelements.ninds.nih.gov
108. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measurepubmed.ncbi.nlm.nih.gov
109. Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29)pubmed.ncbi.nlm.nih.gov
110. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trialspubmed.ncbi.nlm.nih.gov
111. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disabilitypubmed.ncbi.nlm.nih.gov
112. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosispmc.ncbi.nlm.nih.gov
113. Work Adjustments by Types of Occupations Amongst People with Multiple Sclerosis: A Survey Studypmc.ncbi.nlm.nih.gov
114. Education and employmentmsif.org
115. NG220 Evidence review A: Information and support for patients, their families and carersnice.org.uk
116. Recommendations: Supporting adult carersnice.org.uk
117. NG220 Evidence review B: Coordination of carenice.org.uk
118. Atlas of MS 2020—Clinical management reportmsif.org
119. Improve access to MS treatmentmsif.org
120. Global barriers to MS diagnosismsif.org
121. UK MS Register Data Dictionary (PORTAL)ukmsregister.org
122. Home: UK MS Registerukmsregister.org
123. Frequently Asked Questions: Atlas of MSatlasofms.org
124. Multiple Sclerosis | NINDS CDEcommondataelements.ninds.nih.gov
125. NINDS Common Data Elementsninds.nih.gov
126. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studypubmed.ncbi.nlm.nih.gov
127. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis managementpubmed.ncbi.nlm.nih.gov
128. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis managementpmc.ncbi.nlm.nih.gov
129. Imaging chronic active lesions in multiple sclerosis: a consensus statementpubmed.ncbi.nlm.nih.gov
130. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trialpubmed.ncbi.nlm.nih.gov
131. Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosispubmed.ncbi.nlm.nih.gov
132. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trialpubmed.ncbi.nlm.nih.gov
133. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party and JACIEpmc.ncbi.nlm.nih.gov
134. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMTpubmed.ncbi.nlm.nih.gov
135. The path to prevention of multiple sclerosis: Considerations for Epstein-Barr virus vaccine-based prevention studiespubmed.ncbi.nlm.nih.gov